blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1979326

EP1979326 - PYRIDINE AND PYRIMIDINE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  09.08.2013
Database last updated on 25.09.2024
Most recent event   Tooltip17.07.2015Lapse of the patent in a contracting state
New state(s): HU, LU		published on 19.08.2015  [2015/34]
Applicant(s)For all designated states
Janssen Pharmaceutica N.V.
Turnhoutseweg 30
2340 Beerse / BE
[2012/40]
Former [2008/42]For all designated states
Janssen Pharmaceutica, N.V.
Turnhoutseweg 30
2340 Beerse / BE
Inventor(s)01 / MARCONNET-DECRANE, Laurence, Françoise, Bernadette
Johnson & Johnson Pharmaceutical
Research and Development;
Division of Janssen-Cilag
Campus De Maigremont BP 615
F-27106 Val de Reuil Cedex / FR
02 / GAURRAND, Sandrine, Françoise, Dominique
Johnson & Johnson Pharmaceutical
Research and Development;
Division of Janssen-Cilag
Campus De Maigremont BP 615
F-27106 Val de Reuil Cedex / FR
03 / ANGIBAUD, Patrick, René
Johnson & Johnson Pharmaceutical
Research and Development;
Division of Janssen-Cilag
Campus De Maigremont BP 615
F-27106 Val de Reuil Cedex / FR
 [2012/40]
Former [2008/42]01 / MARCONNET-DECRANE, Laurence, Françoise, Bernadette
Johnson & Johnson Pharmaceutical Research and Development; Division of Janssen-Cilag Campus De Maigremont BP 615
F-27106 Val de Reuil Cedex / FR
02 / GAURRAND, Sandrine, Françoise, Dominique
Johnson & Johnson Pharmaceutical Research and Development; Division of Janssen-Cilag Campus De Maigremont BP 615
F-27106 Val de Reuil Cedex / FR
03 / ANGIBAUD, Patrick, René
Johnson & Johnson Pharmaceutical Research and Development; Division of Janssen-Cilag Campus De Maigremont BP 615
F-27106 Val de Reuil Cedex / FR
Representative(s)Vandersteen, Pieter
Johnson & Johnson
Patent Law Department
Turnhoutseweg 30
2340 Beerse / BE
[N/P]
Former [2012/40]Vandersteen, Pieter
Janssen Pharmaceutica N.V. Turnhoutseweg 30
2340 Beerse / BE
Former [2008/42]Vandersteen, Pieter
Janssen Pharmaceutica N.V. Turnhoutseweg 30
2340 Beerse / BE
Application number, filing date07703886.716.01.2007
[2008/42]
WO2007EP50371
Priority number, dateEP2006010057019.01.2006         Original published format: EP 06100570
[2008/42]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2007082874
Date:26.07.2007
Language:EN
[2007/30]
Type: A1 Application with search report 
No.:EP1979326
Date:15.10.2008
Language:EN
The application published by WIPO in one of the EPO official languages on 26.07.2007 takes the place of the publication of the European patent application.
[2008/42]
Type: B1 Patent specification 
No.:EP1979326
Date:03.10.2012
Language:EN
[2012/40]
Search report(s)International search report - published on:EP26.07.2007
ClassificationIPC:C07D213/78, C07D239/42, C07D409/14, C07D403/12, A61K31/506, A61P35/00
[2012/19]
CPC:
A61K31/496 (EP,US); A61K45/06 (US); A61P1/00 (EP);
A61P1/04 (EP); A61P11/00 (EP); A61P11/02 (EP);
A61P11/06 (EP); A61P13/12 (EP); A61P17/00 (EP);
A61P19/00 (EP); A61P19/02 (EP); A61P25/00 (EP);
A61P25/16 (EP); A61P25/18 (EP); A61P25/28 (EP);
A61P27/02 (EP); A61P29/00 (EP); A61P3/06 (EP);
A61P3/10 (EP); A61P33/06 (EP); A61P35/00 (EP);
A61P35/02 (EP); A61P37/04 (EP); A61P37/06 (EP);
A61P43/00 (EP); A61P9/04 (EP); A61P9/10 (EP);
C07D213/78 (EP,US); C07D213/82 (EP,US); C07D239/42 (EP,US);
C07D403/12 (EP,US); C07D409/14 (EP,US); Y02A50/30 (EP,US) (-)
Former IPC [2008/42]C07D239/42, C07D409/14, C07D403/12, A61K31/506, A61P35/00
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2008/42]
Extension statesAL19.08.2008
BA19.08.2008
HR19.08.2008
MK19.08.2008
RS19.08.2008
TitleGerman:PYRIDIN- UND PYRIMIDINDERIVATE ALS INHIBITOREN VON HISTONDEACETYLASE[2008/42]
English:PYRIDINE AND PYRIMIDINE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE[2008/42]
French:DÉRIVÉS DE PYRIDINE ET DE PYRIMIDINE EN TANT QU'INHIBITEURS D'HISTONE DÉSACÉTYLASE[2008/42]
Entry into regional phase19.08.2008National basic fee paid 
19.08.2008Designation fee(s) paid 
15.07.2008Examination fee paid 
Examination procedure15.07.2008Examination requested  [2008/42]
23.07.2010Despatch of a communication from the examining division (Time limit: M06)
24.01.2011Reply to a communication from the examining division
30.04.2012Communication of intention to grant the patent
22.08.2012Fee for grant paid
22.08.2012Fee for publishing/printing paid
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  23.07.2010
Opposition(s)04.07.2013No opposition filed within time limit [2013/37]
Fees paidRenewal fee
02.02.2009Renewal fee patent year 03
01.02.2010Renewal fee patent year 04
31.01.2011Renewal fee patent year 05
31.01.2012Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU16.01.2007
AT03.10.2012
CY03.10.2012
CZ03.10.2012
EE03.10.2012
FI03.10.2012
LT03.10.2012
LV03.10.2012
PL03.10.2012
RO03.10.2012
SI03.10.2012
SK03.10.2012
TR03.10.2012
BG03.01.2013
GR04.01.2013
LU16.01.2013
MC31.01.2013
IS03.02.2013
PT04.02.2013
[2015/34]
Former [2015/32]AT03.10.2012
CY03.10.2012
CZ03.10.2012
EE03.10.2012
FI03.10.2012
LT03.10.2012
LV03.10.2012
PL03.10.2012
RO03.10.2012
SI03.10.2012
SK03.10.2012
TR03.10.2012
BG03.01.2013
GR04.01.2013
MC31.01.2013
IS03.02.2013
PT04.02.2013
Former [2013/37]AT03.10.2012
CY03.10.2012
CZ03.10.2012
EE03.10.2012
FI03.10.2012
LT03.10.2012
LV03.10.2012
PL03.10.2012
RO03.10.2012
SI03.10.2012
SK03.10.2012
BG03.01.2013
GR04.01.2013
MC31.01.2013
IS03.02.2013
PT04.02.2013
Former [2013/35]AT03.10.2012
CY03.10.2012
CZ03.10.2012
EE03.10.2012
FI03.10.2012
LT03.10.2012
LV03.10.2012
PL03.10.2012
SI03.10.2012
SK03.10.2012
BG03.01.2013
GR04.01.2013
IS03.02.2013
PT04.02.2013
Former [2013/34]AT03.10.2012
CY03.10.2012
FI03.10.2012
LT03.10.2012
LV03.10.2012
PL03.10.2012
SI03.10.2012
BG03.01.2013
GR04.01.2013
IS03.02.2013
PT04.02.2013
Former [2013/31]AT03.10.2012
CY03.10.2012
FI03.10.2012
LT03.10.2012
LV03.10.2012
PL03.10.2012
SI03.10.2012
GR04.01.2013
IS03.02.2013
PT04.02.2013
Former [2013/28]CY03.10.2012
FI03.10.2012
LT03.10.2012
LV03.10.2012
PL03.10.2012
SI03.10.2012
GR04.01.2013
IS03.02.2013
PT04.02.2013
Former [2013/24]CY03.10.2012
FI03.10.2012
LT03.10.2012
LV03.10.2012
PL03.10.2012
SI03.10.2012
GR04.01.2013
IS03.02.2013
Former [2013/23]CY03.10.2012
FI03.10.2012
LT03.10.2012
LV03.10.2012
PL03.10.2012
SI03.10.2012
IS03.02.2013
Former [2013/22]FI03.10.2012
LT03.10.2012
SI03.10.2012
IS03.02.2013
Former [2013/20]LT03.10.2012
SI03.10.2012
Former [2013/11]SI03.10.2012
Cited inInternational search[PA]WO2006010749  (JANSSEN PHARMACEUTICA NV [BE], et al) [PA] 1-12 * the whole document *;
 [DY]WO2005030705  (METHYLGENE INC [CA], et al) [DY] 1-12 * the whole document *;
 [DY]WO03092686  (ASTRAZENECA AB [SE], et al) [DY] 1-12 * the whole document *;
 [DY]WO03075929  (JANSSEN PHARMACEUTICA NV [BE], et al) [DY] 1-12 * the whole document *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.